All In Biotech

Drug Trial Radar · NCT06878170

A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Sep 30, 2024

Primary completion

Jan 26, 2026

Study completion Jan 26, 2026

Sponsor

Lead sponsor
Rock BioMedical, Inc.Industry
Sponsor type
Industry
First posted
Mar 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers

Conditions

  • COVID-19

Interventions

  • RBM-001Biological

    To evaluate the safety and tolerability of the RBM-001 vaccination in healthy adults.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence, severity, and relationship of solicited local and general adverse events (AEs) during the 7 days following each vaccination.Time frame: Day 1 to Day 8 after first vaccination, Day 22 to Day 29 after second vaccination
  2. Occurrence, severity, and relationship of unsolicited AEs during the 21 days following each vaccinationTime frame: Day 1 (post-vaccination) to Day 21 for first vaccination, Day 22 (post-vaccination) to Day 43
  3. Occurrence, severity and relationship of adverse events of special interest (AESIs) from the first vaccination through the 28 days following the second vaccination.Time frame: Day 1 through Day 50
  4. Occurrence, severity, and relationship of medically-attended AEs (MAAEs), new-onset chronic medical conditions (NOCMCs), and serious adverse events (SAEs) through the study completionTime frame: Day 1 through Day 383 (End of study follow-up period)
  5. Occurrence of clinically significant changes in clinical laboratory results, vital signs results, 12-lead ECG results, and physical examination findingsTime frame: Day 1 through Day 383 (End of Study)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QPS Miami

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.